A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis

https://doi.org/10.1016/j.jcf.2020.04.012Get rights and content
Under a Creative Commons license
open access

Highlights

  • A report on the outcomes of 40 people with CF who were positive for SARS-CoV-2.

  • The reported cohort is heterogeneous and includes 11 lung transplant patients.

  • The data was collected through the Registries of the 8 participating countries.

  • The clinical course of SARS-CoV-2 in CF appears similar to the general population.

  • The outcomes of this early cases have been better than initially predicted.

Abstract

Information is lacking on the clinical impact of the novel coronavirus, SARS-CoV-2, on people with cystic fibrosis (CF). Our aim was to characterise SARS-CoV-2 infection in people with cystic fibrosis. Methods: Anonymised data submitted by each participating country to their National CF Registry was reported using a standardised template, then collated and summarised. Results: 40 cases have been reported across 8 countries. Of the 40 cases, 31 (78%) were symptomatic for SARS-CoV-2 at presentation, with 24 (60%) having a fever. 70% have recovered, 30% remain unresolved at time of reporting, and no deaths have been submitted. Conclusions: This early report shows good recovery from SARS-CoV-2 in this heterogeneous CF cohort. The disease course does not seem to differ from the general population, but the current numbers are too small to draw firm conclusions and people with CF should continue to strictly follow public health advice to protect themselves from infection.

Keywords

Cystic fibrosis
Coronavirus
SARS-CoV-2

Cited by (0)

1

See Appendix for the list of contributing investigators from the Global Registry Harmonization Group.